Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.

Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology (2015) 2.81

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol (2015) 0.86

Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget (2015) 0.77

Urokinase-type plasminogen activator resulting from endometrial carcinogenesis enhances tumor invasion and correlates with poor outcome of endometrial carcinoma patients. Sci Rep (2015) 0.76

Systematic tracking of disrupted modules identifies significant genes and pathways in hepatocellular carcinoma. Oncol Lett (2016) 0.75

Validation of a Modified Child-Turcotte-Pugh Classification System Utilizing Insulin-Like Growth Factor-1 for Patients with Hepatocellular Carcinoma in an HBV Endemic Area. PLoS One (2017) 0.75

Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma (2015) 0.75

Management of hepatocellular carcinoma. Hepatology (2005) 27.42

Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26

Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27

Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet (1998) 10.11

Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology (2003) 10.11

A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74

Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev (1995) 9.54

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 6.50

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst (1999) 5.27

The insulin-like growth factor system and cancer. Cancer Lett (2003) 4.91

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst (1999) 2.68

Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol (2004) 2.01

Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) (2010) 1.59

MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut (2003) 1.49

Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol (2011) 1.43

Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample. Eur J Endocrinol (2009) 1.18

IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg (2007) 1.15

Assessment of pretransplant prognosis in patients with cirrhosis. Transplantation (1991) 1.13

Insulin-like growth factor-I and the liver. Liver Int (2011) 1.13

Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis. World J Gastroenterol (2005) 1.09

Insulin-like growth factor 1 in hepatocellular carcinoma and metastatic liver cancer in men. Int J Cancer (2000) 1.06

Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol (2010) 1.01

Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology (2011) 0.99

I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score. Oncology (2011) 0.98

Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study. J Clin Lab Anal (2010) 0.98

Growth hormone-stimulated IGF-1 generation in cirrhosis reflects hepatocellular dysfunction. J Hepatol (2008) 0.95

Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol (2004) 0.94

Circulating growth hormone and insulin-like growth factor-I in nonalcoholic liver cirrhosis with or without superimposed hepatocarcinoma: evidence of an altered circadian rhythm. Am J Gastroenterol (1993) 0.93

Can the MEGX test and serum bile acids improve the prognostic ability of Child-Pugh's score in liver cirrhosis? Eur J Gastroenterol Hepatol (1999) 0.89

Insulin-like growth factor I correlates with MELD and returns to normal level after liver transplantation. Ann Transplant (2013) 0.85

Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol (2012) 0.84

Pretreatment assessment of hepatocellular cancer: expert consensus conference. HPB (Oxford) (2010) 0.83

MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease. World J Hepatol (2011) 0.80

[REMOTE RESULTS OF PORTAL SURGERY IN LIVER CIRRHOSIS]. Rev Int Hepatol (1964) 0.78